Who Will Prescribe Mounjaro When You Have Gallstones

Step 1: the prescriber gets the full picture of your gallbladder history

Before anything else, the clinician wants to understand what kind of gallstone history you actually have. There is a meaningful difference between gallstones spotted incidentally on a scan years ago and a recent bout of acute cholecystitis. A GP or private prescriber will typically ask when the stones were diagnosed, whether you have ever had symptoms (biliary colic, jaundice, infection), whether your gallbladder is still in place, and whether any imaging is current.

If you have already had your gallbladder removed (a cholecystectomy) the picture changes considerably. Post-cholecystectomy patients do not face the same risk of stone migration or acute cholecystitis, and many prescribers are more comfortable proceeding in that group. The prescriber will still want to know about any ongoing bile-duct issues, but the principal concern disappears.

Where the gallbladder is still present and stones are documented, the clinician is doing a risk-balance calculation: is the metabolic harm of untreated obesity greater than the incremental gallbladder risk from tirzepatide? For most people with a stable, silent stone history, experienced prescribers answer that question in favour of treating. That said, active biliary disease (ongoing symptoms, recent pancreatitis from a migrating stone) is a reason to pause and stabilise first.

Step 2: understanding why Mounjaro specifically attracts gallbladder caution

Tirzepatide acts on two gut-hormone receptors, GIP and GLP-1, which together slow how quickly food and bile move through the digestive system. Reduced gallbladder contractility means bile sits for longer, and stagnant bile is the environment in which new cholesterol stones form. This is not unique to tirzepatide (semaglutide carries a comparable note) but it is something a careful prescriber factors in for anyone whose gallbladder is already vulnerable.

There is a separate, longer-term consideration. Significant weight loss from any cause, not just GLP-1 medicines, is an established trigger for new gallstone formation as cholesterol is mobilised from fat tissue. A prescriber may therefore discuss low-fat dietary habits during treatment, since high-fat meals provoke stronger gallbladder contractions and the associated pain. That conversation (keeping things like olive oil in check while the pen is in the fridge) is part of proper aftercare, not a warning to avoid treatment.

You can read more about the relationship between GLP-1 treatment and biliary health on our page covering Mounjaro, gallstones and NHS guidance.

Step 3: which type of prescriber will take this on, and how

A GP prescribing on the NHS can theoretically consider Mounjaro for a patient with gallstones, provided the patient meets the phased NHS eligibility criteria, which currently require a BMI of at least 40 alongside multiple qualifying conditions. The reality is that NHS capacity is constrained and the phased rollout means many eligible patients are still waiting. Practices participating in the GP contract from April 2026 onward handle weight-management prescribing, but not all practices have opted in yet.

A GPhC-registered Independent Prescriber working through a regulated private pharmacy (like the prescribers at nume) can assess your gallstone history as part of the standard consultation and make the same clinical judgement, without a referral or a waiting list. The process at nume involves reviewing your full health questionnaire, verifying your identity and weight on video, and checking your Summary Care Record where appropriate. Dose increases and repeat orders go through the same clinical re-review; nothing is automated. If a prescriber has concerns about your gallbladder status at any point, they will tell you directly.

If you want to understand how prescriber authority works more broadly, our guide on who can prescribe Mounjaro in the UK covers the different routes in detail.

Step 4: what the consultation outcome might look like

Most people with a settled gallstone history will be approved, with a note to report any new abdominal symptoms promptly. The prescriber may ask you to be especially attentive in the first weeks of treatment, when GI effects are most noticeable, because nausea, bloating and right-upper-quadrant discomfort can overlap between a GLP-1 side effect and a biliary event, and the distinction matters.

A small number of people will be advised to seek a specialist opinion first: typically those with a very recent biliary episode, active symptoms, or a history of gallstone-related pancreatitis. That is not a permanent door closing; it is a sensible sequencing of care.

Prescribers are also required by MHRA guidance to report any suspected serious reactions via the Yellow Card scheme, and patients can do the same. On the question of cost, if you are weighing private treatment, our page on Mounjaro pricing changes gives an honest account of what the market looks like after Eli Lilly's 2025 list-price revision.

When you are ready, check your eligibility with our prescribers, the consultation is free, and someone reviews your answers the same working day.